GPS Wealth Strategies Group LLC Has $223,000 Holdings in Laboratory Co. of America Holdings (NYSE:LH)

GPS Wealth Strategies Group LLC decreased its holdings in Laboratory Co. of America Holdings (NYSE:LH) by 4.5% in the 4th quarter, Holdings Channel.com reports. The firm owned 974 shares of the medical research company’s stock after selling 46 shares during the period. GPS Wealth Strategies Group LLC’s holdings in Laboratory Co. of America were worth $223,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also recently bought and sold shares of the business. State Street Corp raised its position in shares of Laboratory Co. of America by 0.7% in the third quarter. State Street Corp now owns 3,726,627 shares of the medical research company’s stock valued at $832,827,000 after buying an additional 25,469 shares in the last quarter. Diamond Hill Capital Management Inc. raised its holdings in Laboratory Co. of America by 1.5% in the 3rd quarter. Diamond Hill Capital Management Inc. now owns 1,978,686 shares of the medical research company’s stock valued at $442,197,000 after acquiring an additional 29,046 shares in the last quarter. Geode Capital Management LLC lifted its position in shares of Laboratory Co. of America by 0.7% during the 3rd quarter. Geode Capital Management LLC now owns 1,964,743 shares of the medical research company’s stock valued at $437,561,000 after acquiring an additional 13,298 shares during the period. JPMorgan Chase & Co. grew its holdings in shares of Laboratory Co. of America by 9.5% during the 3rd quarter. JPMorgan Chase & Co. now owns 1,930,395 shares of the medical research company’s stock worth $431,405,000 after purchasing an additional 167,137 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC increased its position in shares of Laboratory Co. of America by 16.4% in the third quarter. Allspring Global Investments Holdings LLC now owns 1,865,460 shares of the medical research company’s stock worth $416,893,000 after purchasing an additional 263,105 shares during the period. Institutional investors own 95.94% of the company’s stock.

Laboratory Co. of America Stock Down 0.9 %

Shares of NYSE LH opened at $249.39 on Monday. Laboratory Co. of America Holdings has a 1 year low of $191.97 and a 1 year high of $258.59. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.44 and a quick ratio of 1.30. The firm has a market cap of $20.86 billion, a PE ratio of 48.24, a price-to-earnings-growth ratio of 1.86 and a beta of 1.07. The company has a 50 day simple moving average of $236.02 and a 200 day simple moving average of $228.63.

Laboratory Co. of America Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, March 12th. Stockholders of record on Thursday, February 27th will be issued a dividend of $0.72 per share. The ex-dividend date is Thursday, February 27th. This represents a $2.88 dividend on an annualized basis and a dividend yield of 1.15%. Laboratory Co. of America’s dividend payout ratio (DPR) is presently 55.71%.

Insider Buying and Selling

In other news, CMO Amy B. Summy sold 3,672 shares of the company’s stock in a transaction on Friday, November 22nd. The shares were sold at an average price of $238.91, for a total value of $877,277.52. Following the sale, the chief marketing officer now directly owns 4,318 shares of the company’s stock, valued at approximately $1,031,613.38. This represents a 45.96 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Der Vaart Sandra D. Van sold 1,000 shares of Laboratory Co. of America stock in a transaction on Thursday, November 21st. The stock was sold at an average price of $239.42, for a total transaction of $239,420.00. Following the transaction, the executive vice president now directly owns 2,670 shares of the company’s stock, valued at $639,251.40. This represents a 27.25 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 24,572 shares of company stock valued at $5,915,209 over the last 90 days. 0.85% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on the stock. HSBC raised shares of Laboratory Co. of America from a “hold” rating to a “buy” rating in a research report on Wednesday, October 30th. Piper Sandler increased their price target on shares of Laboratory Co. of America from $235.00 to $240.00 and gave the stock a “neutral” rating in a research report on Monday, October 28th. UBS Group cut their target price on Laboratory Co. of America from $293.00 to $286.00 and set a “buy” rating for the company in a research note on Tuesday, January 28th. Robert W. Baird lifted their price target on Laboratory Co. of America from $282.00 to $289.00 and gave the company an “outperform” rating in a research note on Friday, October 25th. Finally, StockNews.com downgraded Laboratory Co. of America from a “buy” rating to a “hold” rating in a research report on Friday, October 25th. Four equities research analysts have rated the stock with a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, Laboratory Co. of America has an average rating of “Moderate Buy” and a consensus price target of $261.77.

About Laboratory Co. of America

Labcorp Holdings, Inc engages in providing medical testing services. The company was founded on April 16, 2024 and is headquartered in Burlington, NC.